Neurology News and Research

Latest Neurology News and Research

Opexa Therapeutics reports lower net loss of $1.4M for first-quarter 2010

Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended March 31, 2010 and provided an update on its corporate developments.

14 May 2010

Music enhances new learning of information in AD patients

Researchers from Boston University School of Medicine (BUSM) have shown that patients with Alzheimer's disease (AD) are better able to remember new verbal information when it is provided in the context of music even when compared to healthy, older adults. The findings, which currently appear on-line in Neuropsychologia, offer possible applications in treating and caring for patients with AD.

13 May 2010

Mutations in STRAD-alpha gene can cause PMSE syndrome in Amish children: Penn researchers

So often the rare informs the common. Penn researchers investigating a regulatory protein involved in a rare genetic disease have shown that it may be related to epileptic and autistic symptoms in other more common neurological disorders.

12 May 2010

NeuroMetrix first-quarter total revenues decrease to $3.7 million

NeuroMetrix, Inc., a health care company transforming patient care through neurotechnology, today announced its financial results for the three months ended March 31, 2010.

11 May 2010

Study finds familial restless legs syndrome more prominent among French Canadian women

Restless legs syndrome, which causes an irresistible desire to move legs, appears to be a hereditary condition that's more prominent among French Canadian women and may be caused by a combination of genetic influences and environmental effects. According to a large-scale study published in the Archives of Neurology, siblings of people affected by restless legs syndrome are three and a half times more likely to develop the disease.

11 May 2010

Jazz Pharmaceuticals announces common stock public offering

Jazz Pharmaceuticals, Inc. announced today that it is offering to sell 7 million shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering.

11 May 2010

Eisai enters Canadian pharmaceutical market

Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. today announces the establishment of Eisai Limited in Canada, the world's ninth largest pharmaceutical market. As a wholly-owned subsidiary of Eisai Inc., Eisai Limited will be based in Mississauga, Ontario, one of the largest biopharmaceutical clusters and medical communities in North America.

10 May 2010

Intellipharmaceutics generic Effexor XR ANDA accepted for filing by the FDA

Intellipharmaceutics International Inc., today announced that the Food and Drug Administration (FDA) has accepted for filing its abbreviated new drug application (ANDA) for a generic version of the antidepressant Effexor XR® (venlafaxine hydrochloride).

7 May 2010

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

The Alzheimer's Drug Discovery Foundation announced today that it has awarded a grant of $210,300 to Amicus Therapeutics (Cranbury, NJ) to evaluate small-molecule, orally delivered pharmacological chaperone compounds as a novel approach for treating Alzheimer's disease.

7 May 2010

Survey reveals low awareness of postherpetic neuralgia amongst Americans

The American Pain Foundation (APF) announced today at the American Pain Society (APS) Annual Meeting the results of a national survey that showed postherpetic neuralgia (PHN), also known as after-shingles pain, continues to be a condition with low awareness amongst Americans, demonstrating a need for health care provider (HCP) intervention.

7 May 2010

Natazia tablets receive FDA approval for prevention of pregnancy

Bayer HealthCare Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the prevention of pregnancy.

7 May 2010

Advances in genetic research could help develop personalized pain medications

In the not too distant future, it may be possible to discern an individual's genetic predisposition to chronic pain conditions and treat them proactively to prevent lifetime afflictions, according to research presented today at the American Pain Society's (www.ampainsoc.org) annual scientific meeting.

7 May 2010

54% of liver cirrhosis patients experience neurocognitive impairments

More than half of patients who have cirrhosis of the liver also display neurocognitive impairments such as short term memory loss, a study led by a Loyola University Health System researcher has found.

7 May 2010

Sun Pharmaceutical subsidiary granted USFDA approval for generic Namenda tablets

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.'s Namenda 5 mg and 10 mg tablets.

7 May 2010

Researchers use new tools to study how brain responds when injury occurs

Researchers at four institutions, led by Stanford University and Brown University, have begun an effort with more than $14 million of federal funding to learn both how the brain and its microcircuitry react to sudden physiological changes and what can be done to encourage recovery from injury.

6 May 2010

Researchers discover link between sporadic and familial forms of ALS

Researchers from Northwestern University Feinberg School of Medicine have discovered a link between sporadic and familial forms of amyotrophic lateral sclerosis, a neurodegenerative disease also known as Lou Gehrig's disease.

6 May 2010

Jazz Pharmaceuticals reports 59% increase in first-quarter 2010 revenue

Jazz Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2010 and updated guidance for sales and expenses for 2010.

6 May 2010

Endo Pharmaceuticals to acquire all outstanding shares of HealthTronics common stock

HealthTronics, Inc., a leading provider of urological products and services, today announced that it has signed a definitive merger agreement with Endo Pharmaceuticals pursuant to which Endo will acquire HealthTronics.

6 May 2010

Endo Pharmaceuticals signs agreement to acquire HealthTronics

Continuing to diversify, move into new growth areas beyond pharmaceuticals, and strengthen its commitment to improved patient outcomes in urology, Endo Pharmaceuticals today announced that it has signed an agreement to acquire HealthTronics, Inc., a leading U.S. provider of urological products and services.

6 May 2010

New research suggests tPA can act as neuroprotectant against stroke

New research on the properties of the clot-busting stroke drug tPA (tissue-type plasminogen activator) suggests that tPA can act as a neuroprotectant and may form the keystone of an adaptive response to a reduction in blood flow.

6 May 2010